Investigations of the inhibition of Nr2f6 in mice that used an ex vivo CRISPR/Cas9-mediated gene ablation of Nr2f6 in T cells prior to therapeutic ACT in conjunction with an approved PD-L1 or CTLA-4 ICB therapy improved this therapeutic anti-cancer activity [69]. The gene discussed is CTLA4; the disease is cancer.